Erythropoiesis News and Research

RSS
Infections in older adults may increase risk of hospitalization for dangerous blood clots

Infections in older adults may increase risk of hospitalization for dangerous blood clots

FDA approves Omontys - new anemia drug for chronic kidney disease patients

FDA approves Omontys - new anemia drug for chronic kidney disease patients

New federal drug label recommendations for CKD patients

New federal drug label recommendations for CKD patients

FDA advisory panel OKs anemia drug peginesatide

FDA advisory panel OKs anemia drug peginesatide

Research: lncRNA affects apoptosis and plays a role in RBC development

Research: lncRNA affects apoptosis and plays a role in RBC development

FDA's ODAC to review Affymax peginesatide NDA for treatment of CKD-associated anemia

FDA's ODAC to review Affymax peginesatide NDA for treatment of CKD-associated anemia

Study identifies gene mutation responsible for higher frequency of Italian CDA II

Study identifies gene mutation responsible for higher frequency of Italian CDA II

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

FDA acceptance of peginesatide NDA triggers $10M milestone payment to Affymax

FDA acceptance of peginesatide NDA triggers $10M milestone payment to Affymax

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reports 8% increase in second quarter total product sales to $3,893 million

FDA accepts peginesatide NDA for anemia associated with CKD

FDA accepts peginesatide NDA for anemia associated with CKD

FDA directive on anemia drug in kidney disease patients

FDA directive on anemia drug in kidney disease patients

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

Researchers identify class of drugs that can promote RBC formation in anemic patients

Researchers identify class of drugs that can promote RBC formation in anemic patients

Study: Natural high hemoglobin levels safe for kidney disease patients on dialysis

Study: Natural high hemoglobin levels safe for kidney disease patients on dialysis